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Abstract
Background: Outbreaks of orally transmitted Trypanosoma cruzi continue to be reported in Brazil and are associated with a
high mortality rate, mainly due to myocarditis.
Methods: This study is a detailed report on the disease progression of acute Chagas disease in 13 patients who were
infected during two micro-outbreaks in two northeastern Brazilian towns. Clinical outcomes as well as EKG and ECHO results
are described, both before and after benznidazole treatment.
Results: Fever and dyspnea were the most frequent symptoms observed. Other clinical findings included myalgia,
periorbital edema, headache and systolic murmur. Two patients died of cardiac failure before receiving benznidazole
treatment. EKG and ECHO findings frequently showed a disturbance in ventricular repolarization and pericardial effusion.
Ventricular dysfunction (ejection fraction ,55%) was present in 27.3% of patients. After treatment, EKG readings normalized
in 91.7% of patients. Ventricular repolarization abnormalities persisted in 50% of the patients, while sinus bradycardia was
observed in 18%. The systolic ejection fraction normalized in two out of three patients with initially depressed ventricular
function, while pericardial effusion disappeared.
Conclusions: Myocarditis is frequently found and potentially severe in patients with acute Chagas disease. Benznidazole
treatment may improve clinical symptoms, as well as EKG and ECHO findings.
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Introduction
American trypanosomiasis, or Chagas disease, is a zoonotic
protozoan disease caused by the haemoflagellate Trypanosoma cruzi.
The disease is endemic throughout Central and South America
where about 17 million people are estimated to be infected and
100 million are at risk of infection [1]. In Brazil, the overall
prevalence of Chagas disease is 4.2% and in the northeast region
the infection rate can reach more than 5.0% [1–3]. In endemic
areas, the primary infection usually occurs in children aged 15
years and under. More than 99% of acute Chagas disease cases are
asymptomatic or appear as a nonspecific febrile disease. However,
in untreated patients with severe symptoms of acute Chagas
disease, the mortality rate rises to about 5–10% [1]. Moreover,
30% of infected individuals can develop chronic symptoms of
Chagas disease over a lifetime [4].
Vectorial transmission of Chagas disease has decreased over the
last decade in Brazil. Other forms of transmission, such as blood
transfusion, congenital, organ transplants, and laboratory acci-
dents are reported sporadically [1,4]. The oral-accidental
transmission of Trypanosoma cruzi is becoming increasingly
common.
Since 1965, several outbreaks, possibly caused by oral-
accidental routes, mainly due to ingestion of food, fresh water,
‘‘ac ¸aı ´’’ (Euterpe oleracea) or sugar cane juice, have occurred in many
Brazilian states, including Rio Grande do Sul, Amazonas, Amapa ´,
Santa Catarina, and Bahia [5–14]. In other Latin American
countries, oral transmission has also been reported [15–16]. Oral
infection with T. cruzi is associated with a high mortality rate,
usually in the first two weeks after infection [8–11]. Mortality is
mainly due to acute congestive heart failure, myocarditis and
meningoencephalitis [4,11]. Hemorrhagic manifestations and
severe gastritis have also been reported [6].
Myocarditis is present in 80% of patients presenting severe
symptoms of acute Chagas disease [4,16–17]. Electrocardiogra-
phy (EKG) and echocardiography (ECHO) show alterations such
www.plosntds.org 1 June 2010 | Volume 4 | Issue 6 | e711as atrial fibrillation and pericardial effusion, which are associated
with a poor prognosis [11,17–19]. In this study, we describe
the clinical outcomes of 13 patients, before and after benznida-
zole treatment, during two micro outbreaks of acute Chagas
disease in two towns located in the State of Bahia in northeastern
Brazil.
Materials and Methods
Study Area and Patients
The patients involved in this study came from two neighboring
towns: Macau ´bas (46,554 inhabitants) and Ibipitanga (13,109
inhabitants), both located in the south central region of the state of
Bahia (approximately 700 km from the capital) in the Brazilian
Northeast. In both towns, the annual per capita income is less than
U$1,000 and the UN human development index is 0.62521. In
May 2006, there was an outbreak of acute Chagas disease
involving seven individuals from Macau ´bas (cases 1–7) [8]. All
individuals were members of the same family. Acute Chagas
disease was suspected by a local physician and diagnosis was
laboratory-confirmed in five cases (cases 1–5). Two patients (cases
6, 7) died as a consequence of heart failure before Chagas disease
was confirmed. Oral contamination with T. cruzi probably
occurred via ingestion of improperly stored water, possibly
contaminated by feces of infested T. sordida [8].
The Ibipitanga outbreak occurred a few months after that of
Macau ´bas and involved six cases occurring among a family of 11.
On August 9,2006,thesixcases:father (case 9),threesons (cases10,
12, 13), one daughter (case 11) and his daughter-in-law (case 8) were
working on a sugarcane plantation and drank a freshly-made
sugarcane juice between 8:00 and 9:00 am, which they prepared in
an abandoned sugarcane mill located next to the plantation. The
casesdeveloped symptomsbetween11and21days(betweenAugust
20 and 30, 2006) after the day they drank the sugar cane juice. A
diagnosis of acute Chagas disease was suspected by a local physician
49 days after the ingestion of sugar cane juice (September 27, 2006).
On October 8, 2006, the Epidemiological Surveillance Department
of the Bahia Health Secretariat investigated the outbreak. Twelve
specimens of Triatoma sordida were captured at the sugarcane mill,
one of which was infested with T. cruzi. The diagnosis of Chagas
disease was laboratory-confirmed for all six cases based on positive
serological test results from samples collected on October 8, 2006,
almost 60 days after exposure (Table 1).
Author Summary
Chagas disease is caused by a parasitic protozoan
transmitted to humans by the contaminated feces of
blood-feeding assassin bugs from the Triatominae sub-
family. It may also be transmitted from mother to baby
during pregnancy, by breastfeeding, blood transfusion or
organ transplant. In rare cases, the disease can also be
caused by accidental ingestion of contaminated food
(sugar cane or ac ¸aı ´ juice, drinking water, etc.). Acute
Chagas disease often presents itself as a mononucleosis-
like syndrome, with symptoms including fever, lymph
node enlargement and muscle pain. The mortality rate of
acute Chagas disease is high, mainly due to heart failure as
a consequence of cardiac fiber lesions. There are few
studies describing clinical outcomes and the disease
progression of patients who receive therapeutic treatment,
especially with regard to cardiac exam findings. In this
report, the authors describe clinical findings from two
micro-outbreaks occurring in impoverished towns in
northeastern Brazil. Prior to receiving treatment, patient
mortality rate was 28.6% in one of the outbreaks, and one
pregnant woman experienced a spontaneous abortion
due to the disease in the other outbreak. Most patients
complained of fever, dyspnea, myalgia and periorbital
edema. After receiving a two-month course of treatment,
clinical symptoms improved and the number of abnor-
malities in cardiac exams decreased.
Table 1. Serological test results from 13 patients with acute Chagas disease in two urban outbreaks Bahia, Brazil, 2006.
ID case Parasitological test IFAT (IgM) ELISA (IgM) ELISA recombinant antigens (IgM)
1 Negative Positive n/a n/a
2 Positive Positive n/a n/a
3 Positive Positive n/a n/a
4 Positive Positive n/a n/a
5 Negative Positive n/a n/a
6 n/a n/a n/a n/a
7 n/a n/a n/a n/a
8 Negative Positive Positive Positive
9 Negative Positive Positive Positive
10 Negative Positive Positive Positive
11 Negative Positive Positive Positive
12 Negative Positive Positive Positive
13 Negative Positive Positive Positive
n/a: not available.
cases 1–5: samples collected on May 5, 10 and 15, 2006 (almost 30 days after exposure); cases 6,7: no samples collected (patients died before Chagas disease was
confirmed) [8].
cases 8–13: samples collected on October, 8, 2006 (almost 60 days after exposure). Parasitological tests (thick smear or blood culture): samples processed by FIOCRUZ/
Bahia and Couto Maia Hospital, Bahia, Brazil); IFAT (Indirect immunofluorescence antibody test): samples processed by LACEN-Bahia, Brazil and FUNED- Minas Gerais,
Brazil; ELISA (IgM): samples processed by FUNED- Minas Gerais, Brazil; Elisa with recombinant antigens [20]: samples processed by Edgard Santos University Hospital,
Federal University of Bahia, Brazil.
doi:10.1371/journal.pntd.0000711.t001
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symptoms had repeated negative serological test results for Chagas
disease. All five reported to have drunk the same sugar cane juice
prepared on August 9, 2006 which was also drunk by the six
confirmed cases. However, the five uninfected family members
drank the juice more than four hours after it was prepared and two
of them had boiled the juice prior to ingestion.
The diagnosis for acute Chagas disease was confirmed using
results from positive T cruzi parasitological tests: thick smear or
blood culture; or a positive serologic test for IgM anti-T-cruzi
antibodies: conventional enzyme-linked immunosorbent assay
(ELISA), ELISA with recombinant antigens [20], or an indirect
immunofluorescence antibody test (IFAT) (Table 1).
The study was approved by the institutional review board of
CPqGM-FIOCRUZ, Bahia, Brazil. All patients and/or parents
signed a letter of informed consent prior to examination.
Treatment
All patients were treated after the Chagas diagnosis, which
occurred between seven to 14 days and 27 to 37 days after the
onset of symptoms in the Macau ´bas and Ibipitanga patient groups,
respectively. Oral benznidazole 300mg/day for 60 days was
prescribed according to the Brazilian Consensus of Chagas
Disease [9].
Eletrocardiogram (EKG) and Two-Dimensional Doppler
Echocardiography (ECHO)
The EKG and ECHO were carried out before or shortly after
beginning treatment, and 180 days after the end of specific
treatment for Chagas disease. The criteria to define EKG
alterations were based on the AHA/ACCF/HRS Recommenda-
tions for the Standardization and Interpretation of the Electro-
cardiogram and on the Guidelines of the Brazilian Society of
Cardiology on Analysis and Report Issuance Electrocardiographic
[21,22]. The classification of the severity of the valve disease in
adults was based on the American College of Cardiology/
American Heart Association Practice Guidelines [23] and the
quantification of cardiac chamber size and ventricular mass
followed the criteria from American Society of Echocardiogra-




The most frequent symptoms in the acute phase were fever
(92%) and dyspnea (92%), myalgia (69.2%), periorbital edema
(53.9%), headache, systolic murmur (46.2%), nausea, cough,
abdominal pain, hepatomegaly (38.5%). Thoracic pain and
vomiting were observed in four patients (30.8%), while palpitations
were present in three patients (23.1%) (Table 2). Two patients
(6, 7) from Macau ´bas had heart enlargement, gallop rhythm
(3
rd sound), tachycardia, hypotension, and cardiac failure,
resulting in death. Chest X-rays showed pleural effusion and
cardiac enlargement (Figure 1A and B) in both patients. These
patients were brothers and were the first in their family to develop
the symptoms of this disease. In these cases, the diagnosis of
Chagas disease was based on epidemiological findings alone. The
mortality rate of Chagas disease, before benznidazole treatment,
was 28.6% in Macau ´bas and one pregnant woman from
Ibipitanga experienced a spontaneous abortion prior to receiving
treatment.
EKG and ECHO Alterations
Table 3 displays the most frequent EKG and ECHO findings.
EKG data were available for 12 out of 13 patients. At initial
presentation, all 12 patients had a disturbance of ventricular
repolarization. Right bundle branch block was observed in three
out of 12 patients (25%) (cases 2, 3, 6) and sinus bradycardia was
observed in cases 2, 12 and 13. Atrial fibrillation was present only
in case 4 (8.3%).
ECHO results were available for 11 out of 13 patients. Seven
out of 11 patients had major alterations: a mild degree of mitral
regurgitation was observed in six out of 11 patients (54.6%) (cases
2, 3, 4, 10, 12, 13). Pericardial effusion was observed in cases 2, 3,
4, and 9. Tricuspide regurgitation was found in cases 4, 10 and 13
(27.3%), and dyskinetic septum was observed in cases 3 and 4
(18.2%). Ventricular dysfunction with low ejection fraction ,55%
was present in cases 9, 10 and 12 (27.3%). ECHO findings were
normal for cases 1, 5, 8, and 11.
Effect of Benznidazole Treatment on EKG and ECHO
Alterations
No adverse events during treatment with benznidazole were
observed. As shown in Table 3, EKG results normalized in five out
of 11 patients (91.7%), 180 days after treatment ended.
Ventricular repolarization abnormalities persisted in six out of
11 patients (50%) while sinus bradycardia was observed in two
patients (16.7%). The atrial fibrillation that was present in case 4
ceased after treatment. Regarding ECHO findings, mitral
regurgitation persisted only in cases 3, 4 but disappeared in cases
2, 10, 12, and 13. After treatment, mitral regurgitation was present
in case 9. Ventricular function normalized in cases 9, 10 and 12,
and pericardial effusion was not present.
Table 2. Frequencies of signs and symptoms of thirteen
patients with acute Chagas disease from Macau ´bas and
Ibipitanga, Bahia-Brazil.




Periorbital edema 6 (46.2)
Headache 6 (46.2)
Cardiac murmur 6 (46.2)
Nausea 5 (38.5)
Cough 5 (38.5)
Abdominal pain 5 (38.5)
Hepatomegaly 5 (38.5)
Thoracic pain 4 (30.8)
Vomits 4 (30.8)
Palpitations 3 (23.1)
Edema in legs 2 (15.4)
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Acute Chagas disease caused by oral transmission has been
increasingly reported in Brazil and other Latin American countries
[5–16,25]. However, few studies describe clinical outcomes after
treatment with benznidazole [26]. In this report, the post-
treatment clinical evolution of acute Chagas disease in patients
from two impoverished rural towns in northeastern Brazil was
observed. Oral transmission was determined to be the cause of
both micro-outbreaks of acute Chagas disease. In the Macau ´bas
Figure 1. Chest radiographs showing cardiac enlargement and pulmonary congestion in acute Chagas disease. Patient # 6 (A), 16
years old; patient # 7 (B), 09 years old.
doi:10.1371/journal.pntd.0000711.g001
Table 3. Clinical outcome, electrocardiogram (EKG) and Two-dimensional Doppler Echocardiography (ECHO) of thirteen patients
with acute Chagas disease from Macau ´bas and Ibipitanga, Bahia, Brazil, after benznidazole treatment.
Patient Admission After benznidazole treatment
ID # Heart Failure Age Gender EKG 1 ECHO 1 EKG 2
¥ ECHO 2
¥
1 No 13 F DVR Normal Normal Normal
2 No 18 M RBBB, DVR, SB PEF, MR Normal Normal
3 No 14 F RBBB,DVR PEF, MR, SD DVR MR
4 No 42 F DVR, AFib PEF, MR, TR, SD DVR MR
5 No 11 M DVR Normal DVR Normal
6 Yes, death 16 M RBBB, DVR Not done Not done Not done
7 Yes, death 09 M Not done Not done Not done Not done
8 No 25 F DVR Normal Normal Normal
9 Yes 61 M DVR PEF, EF=52% Normal MR
10 Yes 29 M DVR MR, TR, EF=28% DVR Normal
11 No 24 F DVR Normal Normal Normal
12 Yes 21 M DVR, SB MR, EF=54% DVR, SB Abnormal Relaxation
13 No 37 M DVR, SB MR, TR DVR, SB Normal
Patient #6 and 7 died before evaluation.
¥performed 180 days after the end of benzonidazol treatment.
*MR=Mitral Regurgitation; PEF=Pericardic Effusion; SD=Septum Dyskinesis; DDLV=diastolic Disfunction of Left Ventricule, RBBB=right bundle branch block,
DVR=Disturbance of Ventricular Repolarization, AFib=Atrial Fibrillation, SB=Sinus Bradcardia, TI=Tricuspid Regurgitation.
EKG according the AHA/ACCF/HRS 2009 Recommendations for the Standardization and Interpretation of the Electrocardiogram [21] and Guidelines of the Brazilian
Society of Cardiology 2009 [22].
ECHO according the ACC/AHA 2006 practice guidelines [23] and ASE committee recommendations [24].
doi:10.1371/journal.pntd.0000711.t003
Chagas Oral Transmission in Northeastern Brazil
www.plosntds.org 4 June 2010 | Volume 4 | Issue 6 | e711outbreak, patients were purportedly infected by the ingestion of
stored water contaminated by the feces of infested triatomines [8];
while in Ibipitanga, oral transmission was due to the ingestion of
sugarcane juice prepared in an abandoned sugarcane mill, where
specimens of T. sordida contaminated with T. cruzi were captured.
Fever and dyspnea were experienced by nearly all patients.
Other symptoms and findings indicating myocardial involvement,
such as periorbital edema, chest pain and pericardial effusion,
were observed in more than one-third of patients in both
outbreaks. Hematological and digestive tract symptoms, including
gastrointestinal bleeding and gastritis, were not found in our series,
but were observed in patients from the Santa Catarina outbreak
[6].
Morbidity and mortality rates of severe symptomatic acute
Chagas disease are notably higher in children who contract the
disease [11–12,27]. Moreover, orally transmitted Chagas disease
causes more severe symptoms in acute phases [8–11]. Prior to
receiving treatment, two children from Macau ´bas died as a
consequence of heart failure (28.6% mortality rate), while in
Ibipitanga, one pregnant woman experienced a spontaneous
abortion. In both outbreaks, almost all exposed individuals
developed severe manifestations of acute Chagas disease. In the
Macau ´bas outbreak the attack rate was 100% [8]. In the Ibipitanga
outbreak, the six cases had drunk freshly-made sugarcane juice,
while the five uninfected family members drank the juice more than
four hours after it was prepared and two of them boiled the juice
prior to ingestion. These five individuals remained asymptomatic
and had repeated negative serological test results for Chagas disease.
Insect-derived metacyclic trypomastigotes have specialized mecha-
nisms that allow mucosal invasion. In orally-infected mice,
trypomastigotes are able to invade and replicate in the gastric
mucosa, causing a systemic infection [28–29]. In addition,
metacyclic trypomastigotes taken from a patient who was orally
infected with acute Chagas disease caused high parasitemia and a
high mortality rate in orally-infected mice [30]. The development of
myocarditis in acute Trypanosoma sp. infection is associated with
intenseedemaofthecardiacfibersandthepresenceofinflammatory
infiltrate containing amastigote forms of T. cruzi [4]. High levels of
inflammatory cytokines are associated with myocardial damage. A
recent study found higher levels of interferon-gamma, tumor
necrosis factor-alpha, interleukin-10 and CCL3 in the myocardium
of hamsters exhibiting acute symptoms of Chagas disease, when
compared to asymptomatic animals [31].
EKG and ECHO abnormalities are frequently observed as a
consequence of myocarditis. In the acute phase of Chagas disease,
EKG findings may present alterations including low QRS voltage,
prolonged PR and/or QT intervals, as well as T-wave changes
[4,17]. Ventricular extra systoles, sinus tachycardia, atrial
fibrillation and advanced grade right bundle branch block are
all associated with a poor prognosis [27]. In this study, during the
acute phase of Chagas disease, ECHO exams were normal in only
one-third of patients. Pericardial effusion was observed in 36% of
patients. These findings were similar to those observed by Pinto et
al during the acute phase of Chagas disease [26].
Six-months after the end of treatment with benznidazole, every
patient showed an improvement in clinical symptoms, as well as a
decrease in the number of EKG and ECHO abnormalities.
Clinical signs of cardiac dysfunction, such as ejection fraction by
ECHO, showed improvement in patients with more severe cardiac
manifestations (cases 9, 10 and 12). In addition, 45% of patients (5
out of 11) with acute Chagas disease had a normal EKG at the end
of treatment. We cannot conclude that improvements in EKG and
ECHO findings were directly attributable to therapy, as opposed
to the natural course of the disease. Although there is ample
information on the clinical evolution of chronic Chagas disease,
there are few studies that have evaluated the effect of benznidazole
treatment on EKG and ECHO exams in patients with acute
Chagas disease who have been followed from initial presentation
to convalescence [11,26–27]. In children in the early chronic
phase of Chagas disease, after three to four years of follow-up, no
conclusive evidence was obtained to indicate that benznidazole
treatment, when compared with a placebo, could revert EKG
abnormalities [32–33]. However, adults with indeterminate and
chronic Chagas disease who were treated with benznidazole
developed fewer electrocardiographic abnormalities when com-
pared with untreated patients [34]. The present study exclusively
involved patients in the acute phase of Chagas disease, for whom
treatment is mandatory [8]. As such, it would be unethical to
deprive these patients of treatment, making a clinical trial with a
placebo control impossible. The efficacy of benznidazole in acute
Chagas disease is demonstrated by a reduction in parasite load
[35]. The cure rate for parasitological acute Chagas disease ranges
from 60 to 80%, depending on patient age, dosage and whether
treatment was initiated at the beginning of the infection [36–37].
We can conclude that cardiac alterations occur frequently, and
are potentially severe, in the acute phase of orally transmitted
Chagas disease. Furthermore, EKG and ECHO findings may
have an impact on the clinical management of the disease,
enabling monitoring of disease progression both during and after
benznidazole treatment. Further studies are necessary to evaluate
the persistence of EKG and ECHO abnormalities over the long
term, as well as morbidity and mortality.
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